Literature DB >> 18237845

Quantifying hypertension in patients with cancer treated with sorafenib.

Brian I Rini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18237845     DOI： 10.1016/S1470-2045(08)70009-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.

Authors:  Dorothy Keefe; Joanne Bowen; Rachel Gibson; Thean Tan; Meena Okera; Andrea Stringer
Journal:  Oncologist       Date:  2011-03-25

2.  PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors.

Authors:  Julia C F Quintanilha; Alessandro Racioppi; Jin Wang; Amy S Etheridge; Stefanie Denning; Carol E Peña; Andrew D Skol; Daniel J Crona; Danyu Lin; Federico Innocenti
Journal:  Pharmacogenomics J       Date:  2021-11-13       Impact factor: 3.245

3.  Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

Authors:  Michael L Maitland; Kristen E Kasza; Theodore Karrison; Kristin Moshier; Laura Sit; Henry R Black; Samir D Undevia; Walter M Stadler; William J Elliott; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

Review 4.  Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.

Authors:  Ming Hui Chen
Journal:  Curr Cardiol Rep       Date:  2009-05       Impact factor: 2.931
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.